๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Peking Union Medical College Hospital276 Beijing Tiantan Hospital214 Cancer Institute and Hospital, Chinese Academy of Medical Sciences197 AstraZeneca183 Peking University People's Hospital158
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Beijing

5484 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer
NCT06869226Esophageal Cancer
Peking University Cancer Hospital & Institute
Phase 2
283
Beijing
2025-04-30
Recruiting
A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer
NCT06938321Biliary Tract Cancer
Akeso
Phase 1/2
135
Beijing
2025-04-30
Recruiting
A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer
NCT06623136Non-Small Cell Lung Cancer
Elpiscience (Suzhou) Biopharma, Ltd.
Phase 2
40
Beijing, Zhengzhou, Nanchang, Changchun, Jinan, Luoyang, Taiyuan, Taizhou
2025-04-30
Recruiting
Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
NCT06813911Atherosclerotic Cardiovascular Disease (ASCVD)
Novartis Pharmaceuticals
Phase 3
340
Yinchuan, Jining, Xian, Beijing, Shanghai
2025-04-30
Recruiting
Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer
NCT07066995Pancreatic Cancer, Pancreatic Carcinoma, Pancreatic Cancer Non-resectable, Pancreatic Cancer Stage IV
Essen Biotech
Phase 1/2
60
Beijing
2025-04-29
Recruiting
Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma
NCT07032129Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma Progression, Multiple Myeloma, Refractory
Essen Biotech
Phase 1/2
60
Beijing
2025-04-29
Active, closed
Study for AZD4360 in Participants With Advanced Solid Tumours
NCT06921928Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
AstraZeneca
Phase 1/2
31
Beijing, Chengdu, Shanghai, Wuhan
2025-04-29
Recruiting
A Trial of SHR-1314 Injection in Adult Patients With Active Non-radiographic Axial Spondyloarthritis
NCT06860750Active Non-radiographic Axial Spondyloarthritis
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3
380
Beijing
2025-04-29
Recruiting
Clinical Study on the Efficacy and Safety of TNTL in the Treatment of Non-proliferative Diabetic Retinopathy
NCT06817265Non-Proliferative Diabetic Retinopathy
Beletalent (Zhuhai) Pharmaceutical Co., Ltd
Phase 3
360
Xuancheng, Beijing, Guangzhou, Shenzhen, Zhuhai, Guiyang, Shijiazhuang, Kaifeng
2025-04-29
Recruiting
Sequential CD146 and GPC3 CAR-T Cell Therapy in Advanced Ovarian Cancer
NCT07067255Ovarian Cancer, Ovarian Carcinoma, Ovarian Sarcoma, Ovarian Cancer Stage IV
Essen Biotech
Phase 1/2
80
Beijing
2025-04-29
Recruiting
Clinical Outcomes of Drug-Coated Balloons in the Treatment of Patients With Coronary De Novo Chronic Total Occlusion Lesions
NCT07463664Chronic Total Occlusions of Coronary Arteries, Chronic Total Occlusion (CTO), Coronary Artery Disease (CAD)
The First Affiliated Hospital of Zhengzhou University
Not applicable
200
Beijing, Anyang, Jiaozuo, Jiyuan, Kaifeng, Luoyang, Nanyang, Pingdingshan
2025-04-28
Recruiting
A Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant Tumour
NCT06915142Advanced Malignant Tumour
Shandong Suncadia Medicine Co., Ltd.
Phase 2
300
Beijing, Tianjin
2025-04-28
Recruiting
Preoperative Sleep Intervention on Postoperative Delirium in School-aged Children Undergoing Congenital Heart Surgery
NCT06879431Delirium - Postoperative, Sleep Problems, Congenital Heart Disease (CHD)
Yan Fuxia
Not applicable
544
Beijing
2025-04-28
Recruiting
The Efficacy and Safety of Inpegsomatropin Injection in Children With Idiopathic Short Stature
NCT06927310Idiopathic Short Stature
Xiamen Amoytop Biotech Co., Ltd.
Phase 3
300
Hefei, Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou, Zhengzhou, Wuhan
2025-04-28
Recruiting
Study on the Application of Liquid Chromatography-Tandem Mass Spectrometry for the Determination of Aldosterone and Renin Activity in the Diagnosis of Primary Aldosteronism by Captopril Test
NCT07691801Primary Aldosteronism
Peking Union Medical College Hospital
Observational
800
Beijing
2025-04-28
Recruiting
Cerebral Large Vessel Occlusion Stroke Multiomics Biosample Cohort
NCT06963489Large Vessel Occlusion, Acute Ischemic Stroke
First Affiliated Hospital of Wannan Medical College
Observational
500
Wuhu, Baotou, Jinan, Henan, Beijing
2025-04-27
Recruiting
Phase I Clinical Study of YK1101 Injection for the Treatment of Advanced Solid Tumors
NCT07139067Advanced Solid Tumor Cancer
Peking University
Phase 1
10
Beijing
2025-04-27
Recruiting
SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer
NCT06859775Recurrent or Metastatic Cervical Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2
100
Beijing
2025-04-25
Recruiting
pBFS Guided aiTBS Over Language Network for ASD Child
NCT06950437Autism Spectrum Disorder, Language Delay
Beijing Changping Tianhe Research Institute of Brain Science
Not applicable
150
Beijing
2025-04-25
Active, closed
Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure
NCT06935409Osteosarcoma
Hansoh BioMedical R&D Company
Phase 3
117
Beijing
2025-04-25
Not yet open
Efficacy of Fuzheng Tongfu Jiedu Prescription for Treating Gastrointestinal Dysfunction Associated With Sepsis
NCT06933238Sepsis Abdominal, Gastrointestinal Dysfunction, Traditional Chinese Medicine
Dongzhimen Hospital, Beijing
Phase 1/2
70
Beijing
2025-04-25
Recruiting
Neuronavigation-assisted Stereotactic Puncture With Tenecteplase for Acute Intracerebral Hemorrhage
NCT06868511Deep Intracerebral Hemorrhage (ICH)
Beijing Tiantan Hospital
Phase 3
732
Beijing
2025-04-25
Recruiting
Comparison of 5G-Mobile Stroke Unit With Standard EMS for Acute Ischemic Stroke
NCT06943885Acute Ischemic Stroke
Beijing Emergency Medical Center
Not applicable
952
Beijing
2025-04-25
Recruiting
Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors
NCT06414460Locally Advanced/Metastatic Solid Tumors
InSilico Medicine Hong Kong Limited
Phase 1/2
146
Beijing, Guangzhou, Nanjing, Shanghai
2025-04-25
Recruiting
Sapien 3 Transcatheter Aortic Valve Replacement in Young Aortic Valve Stenosis Patients From China
NCT06830499AORTIC VALVE DISEASES, Bicuspid Aortic Valve (BAV)
Xijing Hospital
Observational
450
Xi'an, Chengdu, Beijing, Shanghai
2025-04-24
Recruiting
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
NCT06875310Carcinoma, Non-Small-Cell Lung
Mirati Therapeutics Inc.
Phase 3
630
Bengbu, Hefei, Beijing, Chongqing, Fuzhou Fujian, Xiamen, Guangzhou, Shantou
2025-04-24
Recruiting
A Trial of HRS-6768 in Patients With Advanced Solid Tumors
NCT06925581Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
84
Beijing, Shanghai
2025-04-24
Recruiting
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
NCT06880770Severe Hypertriglyceridemia
Arrowhead Pharmaceuticals
Phase 3
288
Beijing, Guangzhou, Guiyang, Harbin, Luoyang, Nanyang, Zhuzhou, Baotou
2025-04-24
Recruiting
A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma
NCT06929624Diffuse Large B-cell Lymphoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3
280
Beijing, Guangzhou
2025-04-24
Recruiting
A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal Cancer
NCT06885385Advanced Colorectal Cancer
Shanghai Junshi Bioscience Co., Ltd.
Phase 2
60
Beijing, Shanghai
2025-04-23
Recruiting
BCI-Assisted SCS-EXS for Gait Optimization
NCT06939660Spinal Cord Injuries (SCI), Spinal Cord Injury, Chronic, Spinal Cord Injury, Spinal Cord Injury Cervical
Xuanwu Hospital, Beijing
Not applicable
3
Beijing
2025-04-23
Recruiting
Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
NCT06829771Diffuse Large B Cell Lymphoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
90
Bengbu, Maโ€™anshan, Beijing, Fuzhou, Quanzhou, Lanzhou, Guangzhou, Liuzhou
2025-04-23
By invitation
Healthy Adult Reference Biobank for Cardiovascular Biomarkers in China
NCT07136675Healthy Individuals (Controls)
China National Center for Cardiovascular Diseases
Observational
2,400
Beijing
2025-04-22
Recruiting
A Phase IIa Study to Evaluate NBQ72S
NCT06810804Breast Cancer
Nantong Bencao Quadriga Medical Technology Co. Ltd.
Phase 2
10
Beijing
2025-04-22
Active, closed
Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS060304 in Healthy and Elevated LDL-C Subjects
NCT06485245MASH
Cascade Pharmaceuticals, Inc
Phase 1
80
Beijing
2025-04-22
Recruiting
Coated Aldehyde Oxystarch for Protein-Bound Uremic Toxin Reduction in End-Stage Renal Disease
NCT07653711End Stage Renal Disease on Dialysis
Peking University People's Hospital
Not applicable
30
Beijing
2025-04-21
By invitation
Efficacy and Safety of Human Urinary Kallidinogenase for Acute Ischemic Stroke Patients Receiving Reperfusion Treatment
NCT06848894Acute Ischemic Stroke
Beijing Tiantan Hospital
Not applicable
1,204
Beijing
2025-04-21
Recruiting
Efficacy of Neoadjuvant Immunotherapy in Patients With Lung Cancer
NCT07166003Lung Cancer, Non-Small Cell, Immunotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
500
Beijing
2025-04-20
Recruiting
Remote Ischemic Conditioning for Non-Proliferative Diabetic Retinopathy
NCT06713720Diabetic Retinopathy, Non-Proliferative Diabetic Retinopathy, Remote Ischemic Conditioning, Diabetes Mellitus, Type 2
Xuxiang Zhang, MD
Not applicable
68
Beijing
2025-04-20
Active, closed
Effects of HIPEC on Postoperative Bowel Motility and Complications
NCT07353177HIPEC, Gastro Intestinal Cancer, Adhesion Prevention, Bowel Functions
Peking University People's Hospital
Observational
193
Beijing
2025-04-20
Recruiting
A Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type)
NCT06962267Pancreatic Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
50
Beijing
2025-04-18
Active, closed
Critical Closing Pressure and PCOโ‚‚ Gap in Fluid Resuscitation for Septic Shock
NCT07043192Septic Shock, Fluid Resuscitation, Tissue Perfusion Pressure, Carbon Dioxide Pressure
Peking Union Medical College
Observational
60
Beijing
2025-04-18
Recruiting
CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH
NCT06947460Refractory Lupus Nephritis, Systemic Sclerosis, Primary Sjogren's Syndrome Combined With Pulmonary Hypertension, Other Autoimmune Diseases (AID)
Beijing GoBroad Hospital
Phase 1/2
45
Beijing
2025-04-18
Recruiting
A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma
NCT06860971Thyroid Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
144
Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Gui'lin, Liuzhou
2025-04-18
Recruiting
Pulsed Field Ablation Outcomes With Efficacy and Randomization in Atrial Fibrillation (POWER-AF)
NCT07601763Atrial Fibrillation (AF), Atrial Fibrillation Ablation, Atrial Fibrillation Recurrent, Pulsed Field Ablation
China National Center for Cardiovascular Diseases
Not applicable
1,574
Beijing
2025-04-16
Recruiting
A Clinical Study of YTS109 Cell in R/R Systemic Lupus Erythematosus
NCT06943937Lupus Nephritis (LN), Immune Thrombocytopenia (ITP)
China Immunotech (Beijing) Biotechnology Co., Ltd.
Phase 1
36
Beijing
2025-04-16
Recruiting
The Efficacy and Safety of Venostan in Promoting Postoperative Swelling Reduction in Patients With Ankle Fractures
NCT06872034Swelling/ Edema
Beijing Jishuitan Hospital
Not applicable
290
Beijing
2025-04-16
Recruiting
Clinical Study on Prostate Thermal Vapor Ablation Guided by MRI/TRUS Fusion Imaging
NCT06817733Benign Prostatic Hyperplasia (BPH)
Chinese PLA General Hospital
Not applicable
30
Beijing
2025-04-15
Recruiting
EV + Toripalimab vs GC as Neoadjuvant Therapy in Locally Advanced/High-Risk MIBC
NCT07647289Muscle-Invasive Bladder Cancer (MIBC)
Peking University Third Hospital
Phase 2
58
Beijing
2025-04-15
Not yet open
Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer
NCT06931145Extensive-stage Small Cell Lung Cancer
Peking Union Medical College Hospital
Phase 4
50
Beijing
2025-04-15
Recruiting
A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple Myeloma
NCT06717113Multiple Myeloma and Malignant Plasma Cell Neoplasms
Peking University First Hospital
Phase EARLY_PHASE1
50
Beijing
2025-04-15
Active, closed
Phase Ib Clinical Study to Evaluate the Safety and Tolerability of VSA012 Injection in Paroxysmal Nocturnal Hemoglobinuria
NCT06848296Paroxysmal Nocturnal Hemoglobinuria (PNH)
Bisirna Therapeutics Pte. Ltd.
Phase 1
50
Beijing, Hangzhou
2025-04-15
Recruiting
FAPI Imaging Predicts Adverse Cardiac Events in Chronic Total Occlusion
NCT07020858Chronic Total Occlusion (CTO), Chronic Coronary Syndrome
Lin Zhao
Observational
470
Beijing
2025-04-15
Recruiting
Iparomlimab and Tuvonralimab (QL1706) for Intermediate Trophoblastic Tumors
NCT06941766Intermediate Trophoblastic Tumor
Peking Union Medical College Hospital
Phase 1/2
20
Beijing
2025-04-15
Not yet open
Assessing Coronary Non-Culprit Plaque Early with Start of PCSK9 Inhibitors in Acute Myocardial Infarction (ACCESS-AMI)
NCT06854523Acute Myocardial Infarction
Yun Dai Chen
Not applicable
300
Beijing
2025-04-15
Recruiting
Clinical Intelligent Management System - Multilingual Exploration
NCT06923410Primary Care Diseases
Tsinghua University
Not applicable
40
Beijing
2025-04-15
Recruiting
Efficacy and Safety of the RD Regimen(Lenalidomide, Dexamethasone) for Rosai-Dorfman Disease
NCT07187167Rosai-Dorfman Disease
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
40
Beijing
2025-04-12
Recruiting
Efficacy and Safety of Low-Dose Cytarabine Combined With Thalidomide in Adult Patients With Untreated LCH
NCT07187193Langerhans Cell Histiocytosis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
50
Beijing
2025-04-12
Recruiting
Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ยฑ Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C
NCT06821503Advanced Pancreatic Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
72
Beijing, Chongqing, Harbin, Zhengzhou, Wuhan, Nanjing, Nanchang, Shenyang
2025-04-11
Recruiting
A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment
NCT06987500Tumor, Solid
Evopoint Biosciences Inc.
Phase 1/2
132
Beijing
2025-04-11
Recruiting
Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Renal Impairment and Normal Renal Function
NCT07141030Obesity/Overweight
Gan & Lee Pharmaceuticals.
Phase 1
32
Beijing
2025-04-11
Recruiting
A Trial of Dextromethorphan and Bupropion Sustained-Release Tablets in Patients With Major Depressive Disorder
NCT06958692Major Depressive Disorder (MDD)
CSPC Ouyi Pharmaceutical Co., Ltd.
Phase 3
388
Beijing
2025-04-11
Recruiting
Randomized Controlled Trial on the Efficacy and Safety of Xiang Lei Ointment in Diabetic-related Ulcer Management
NCT06841237Diabetic Wound, Wound Infection, Wound Heal
Peking University Third Hospital
Not applicable
56
Beijing
2025-04-10
Not yet open
A Prediction Model of Prolonged Mechanical Ventilation Following Acute Type A Aortic Dissection Surgery
NCT06929780Acute Type A Aortic Dissection
China-Japan Friendship Hospital
Observational
1,400
Beijing
2025-04-10
Recruiting
Safety and Efficacy of Edoxaban and Rivaroxaban to Cerebral Venous Thrombosis in Chinese Patients
NCT06947707Cerebral Venous Thrombosis, Anticoagulants and Thrombotic Disorders, Anticoagulation Treatment, Anticoagulant Therapy
Xuanwu Hospital, Beijing
Observational
1,486
Beijing
2025-04-10
Not yet open
Efficacy of Remote Ischemic Conditioning in Preventing Post-Stroke Depression
NCT06920706Post-stroke Depression, Remote Ischemic Conditioning
Xuanwu Hospital, Beijing
Not applicable
240
Tongren, Baoding, Jilin City, Jincheng, Beijing
2025-04-10
Recruiting
Study on the Efficacy and Safety of HRS-7535 in Patients With Mild Decrease in Ejection Fraction/Preserved Ejection Fraction Heart Failure and Obesity
NCT06820099Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
Shandong Suncadia Medicine Co., Ltd.
Phase 2
225
Beijing
2025-04-10
Recruiting
The Effectiveness of Group Guided Written Exposure Therapy for CPTSD Symptoms Among Adolescents
NCT06931093CPTSD, Compelx Post-traumatic Stress Disorder
Peking University
Not applicable
120
Beijing
2025-04-10
Recruiting
A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
NCT06776952Relapsed/Refractory Peripheral T Cell Lymphoma
Evopoint Biosciences Inc.
Phase 3
120
Beijing
2025-04-10
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
NCT06868277Carcinoma, Non-Small Cell Lung
AstraZeneca
Phase 3
830
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou
2025-04-10
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693Breast Cancer
Hoffmann-La Roche
Phase 3
450
Xiangyang, Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jiangmen
2025-04-09
Recruiting
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
NCT06822790Hypertriglyceridemia
Arrowhead Pharmaceuticals
Phase 3
869
Bengbu, Beijing, Guangzhou, Liuzhou, Xingtai, Luoyang, Changsha, Wuhan
2025-04-09
Recruiting
Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease
NCT06793475Extramedullary Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
20
Beijing, Tianjin
2025-04-09
By invitation
To Evaluate the Efficacy and Safety of TRD205 Tablets in the Treatment of Chronic Postoperative Neuralgia
NCT07123402Chronic Postoperative Neuralgia
Beijing Tide Pharmaceutical Co., Ltd
Phase 2
184
Beijing
2025-04-09
By invitation
Phase III Trial of VDJ001 In Patients With Moderate-to-severe Active Rheumatoid Arthritis
NCT06726096Rheumatoid Arthritis (RA), Anti IL-6R
Beijing VDJBio Co., LTD.
Phase 3
615
Beijing
2025-04-09
Recruiting
An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome
NCT05066217Lennox Gastaut Syndrome
Epygenix
Phase 3
260
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Jinan
2025-04-09
Recruiting
Efficacy and Safety of Catheter abLation in patiEnts With seVere mitrAl regurgiTation and pErsistent Atrial Fibrillation: a Randomized Controlled Trial
NCT06883864Atrial Fibrillation (AF), Catheter Ablation, Atrial Functional Mitral Regurgitation
Beijing Anzhen Hospital
Not applicable
146
Hefei, Beijing, Xiamen, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan
2025-04-08
Recruiting
ctDNA-MRD Monitoring After Resection in Gastric Cancer
NCT06893133Gastric Cancer
Peking University
Observational
110
Beijing
2025-04-08
Recruiting
Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure
NCT07087223Non Small Cell Lung Cancer NSCLC
Peking University Cancer Hospital & Institute
Phase 1/2
42
Neimeng, Baoding, Baotou, Beijing, Dalian, Tianjin
2025-04-08
Recruiting
Clinical Studies for the Treatment of Advanced Solid Tumors
NCT06825494Advanced Solid Tumor
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1/2
194
Hefei, Beijing, Fuzhou, Lanzhou, Wuwei, Shenzhen, Nanning, Tangshan
2025-04-08
Recruiting
A Study of Treatment-Related Toxicities and Quality of Life After Local Therapy in Chinese Breast Cancer Patients
NCT07010939Breast Neoplasms, Quality of Life (QOL), Toxicities, Breast Diseases
FangYi
Observational
3,000
Beijing, Shenzhen, Taiyuan
2025-04-07
Not yet open
A Mass Balance Study of [14C]ABSK011
NCT06896760Healthy Subjects
Abbisko Therapeutics Co, Ltd
Phase 1
6
Beijing
2025-04-07
Recruiting
A Study of SRSD216 in Patients With Elevated Lipoprotein (a)
NCT07172646Hyperlipoproteinemia (a)
Sirius Therapeutics Co., Ltd.
Phase 1/2
84
Beijing
2025-04-07
Recruiting
BC008-1A Injection for Recurrent CNS WHO G4 Glioma
NCT06773481Glioma, Glioma Tumor Recurrence, Glioma, Recurrent High Grade, Glioblastomas (GBM)
Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.
Phase 1
40
Beijing
2025-04-07
Recruiting
Adaptive Therapy for Resected Stage โ… A2-โ…ก NSCLC Patients With Undetectable MRD
NCT06924710NSCLC
Peking University Cancer Hospital & Institute
Not applicable
286
Beijing
2025-04-06
Active, closed
Efficacy and Safety of Laparoscopic Lateral Suspension and Transvaginal Sacrospinous Ligament Fixation in Patients With Pelvic Organ Prolapse
NCT06903988Pelvic Organ Prolapse (POP)
Peking University People's Hospital
Not applicable
86
Beijing
2025-04-05
Active, closed
Laparoscopic Myomectomy Based on a Fully Enclosed Protective Device: A Novel Surgical Technique Achieving Tumor-Free Protection Throughout the Entire Procedure
NCT07474688Uterine Fibroids (Leiomyoma)
China-Japan Friendship Hospital
Observational
20
Beijing
2025-04-04
Recruiting
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
NCT06801834Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Gilead Sciences
Phase 3
695
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin
2025-04-04
Recruiting
A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs
NCT06829459Non-Small Cell Lung Cancer
Shanghai JMT-Bio Inc.
Phase 3
350
Beijing
2025-04-03
Active, closed
A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular Carcinoma
NCT07713290Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Cancer
Beijing Gene Key Life Technology Co., Ltd
Phase 1
6
Beijing, Taiyuan
2025-04-03
Recruiting
A Study of BGM0504 in Participants With Obesity
NCT06911203Obesity
BrightGene Bio-Medical Technology Co., Ltd.
Phase 2
90
Beijing
2025-04-03
Recruiting
A Trial of HRS-8427 in the Treatment of Adults With Bacterial Pneumonia
NCT06841731Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP)
Jiangsu HengRui Medicine Co., Ltd.
Phase 2
100
Beijing
2025-04-03
Not yet open
Preemptive Analgesia Of Dexmedetomidine Reduces Per-operation Pain
NCT06671327Pain Management, Noncardiac Surgery
China International Neuroscience Institution
Phase 4
208
Beijing
2025-04-03
Not yet open
7.0T Magnetic Resonance Imaging Study for Hepatic Encephalopathy
NCT06923254Hepatic Encephalopathy (HE), MRI, fMRI Research
Chinese PLA General Hospital
Observational
200
Beijing
2025-04-03
Recruiting
Effects of Low-Sodium Salt on Death, HF Hospitalization/ Emergency Department Visits and Quality of Life in HF Patients
NCT06764225Heart Failure, Dietary Sodium Intake
Heart Health Research Center
Not applicable
1,301
Beijing
2025-04-03
Recruiting
Efficacy and Safety of SLIT in Patients With Rhinitis/RC With/Without Mild-moderate Asthma, Due to Dpt and/or Df
NCT07348302Rhinitis, Rhinoconjunctivitis
Inmunotek S.L.
Phase 3
736
Beijing, Guangzhou, Zhongshan, Xiangya, Changzhou, Qingdao, Shanghai, Tongji
2025-04-02
By invitation
Clinical Study on Lymphaticovenous Anastomosis๏ผˆLVA๏ผ‰ for the Treatment of Alzheimer's Disease๏ผˆAD๏ผ‰
NCT06918145Alzheimer&Amp;#39;s Disease (AD)
Peking University Third Hospital
Not applicable
80
Beijing
2025-04-02
Recruiting
Application of Methylation Markers in Early Detection and MRD Monitoring of Lung Cancer
NCT07257458Lung Cancer (NSCLC)
Beijing Haidian Hospital
Observational
30
Beijing
2025-04-02
Recruiting
A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD
NCT06346600Neovascular (Wet) Age-related Macular Degeneration
Skyline Therapeutics
Observational
83
Hefei, Hangzhou, Wenzhou, Beijing, Shanghai
2025-04-02
Recruiting
Monitoring Hyperkalemia Using Point-of-care AI-enabled ECG Device Among Patients With Chronic Kidney Disease Stages 3b-5
NCT06901960Chronic Kidney Disease (Stages 3b-5)
Peking University First Hospital
Not applicable
1,066
Beijing, Nanning, Wuhan
2025-04-02
Rows per page Showing 2301–2400 of 5484
Previous 22 23 24 25 26 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 23 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing?page=24

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 5,484 of those studies with a site in Beijing.

How many clinical trials are recruiting in Beijing?

3,341 of the 5,484 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 966 have not yet opened recruitment, 1,001 are active but closed to new participants, and 176 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.